论文部分内容阅读
目的观察力尔凡在恶性胸腔积液治疗中的疗效。方法将2002年1月至2006年6月确诊为恶性胸腔积液的患者随机分为治疗组21例和对照组21例。均采用小导管闭式引流置管技术,将一细硅胶管置入胸膜腔,待引出胸液后,治疗组向胸膜腔内注入力尔凡,对照组注入白介素-2。观察两组治疗效果及副作用。结果治疗组完全缓解率76.19%,对照组61.90%。治疗组中有2例低热,对照组有3例低热,均未出现剧烈胸痛,两组治疗前后血常规、肝功、肾功均正常。结论力尔凡治疗恶性胸腔积液疗效满意,副作用少,值得在恶性胸腔积液的治疗中推广应用。
Objective To observe the efficacy of Lerfan in the treatment of malignant pleural effusion. Methods Patients diagnosed with malignant pleural effusion from January 2002 to June 2006 were randomly divided into treatment group (21 cases) and control group (21 cases). All catheters were closed with a small catheter, and a thin silicone tube was inserted into the pleural cavity. After the pleural fluid was drawn, the treatment group was injected with rilfan into the pleural cavity and the control group was injected with IL-2. Observed two groups of treatment effects and side effects. Results The complete remission rate was 76.19% in the treatment group and 61.90% in the control group. In the treatment group, there were 2 cases of hypothermia, and in the control group there were 3 cases of hypothermia, all without severe chest pain. The blood routine, liver function, and renal function were normal before and after treatment. Conclusion The efficacy and safety of Lierfan in the treatment of malignant pleural effusion is satisfactory and has few side effects. It is worthy of promotion in the treatment of malignant pleural effusion.